DigestRedComo funciona
Red
/
Empresas
Ba
No verificado

Basilea Pharmaceutica International Ltd, Allschwil

Sobre qué escribimos

Anuncios brevesBiotecnologíaGestión empresarial/Administración de EmpresasMedicina Salud BienestarPolítica Internacional

11 Comunicados de prensa

Ver todos los comunicados de prensa
13/09/2026
Biotecnología
Anuncios breves
Medicina Salud Bienestar
Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients
Fuente
Basilea Pharmaceutica International Ltd, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
17/08/2026
Biotecnología
Anuncios breves
Política Internacional
Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track
Fuente
Basilea Pharmaceutica International Ltd, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
04/08/2026
Biotecnología
Medicina Salud Bienestar
Política Internacional
Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Fuente
Basilea Pharmaceutica International Ltd, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
28/07/2026
Biotecnología
Medicina Salud Bienestar
Política Internacional
Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
Fuente
Basilea Pharmaceutica International Ltd, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
27/05/2026
Biotecnología
Medicina Salud Bienestar
Anuncios breves
Política Internacional
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Fuente
Basilea Pharmaceutica International Ltd, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
15/04/2026
Biotecnología
Anuncios breves
Basilea shareholders approve all proposals of the board of directors at the 2026 annual general meeting
Fuente
Basilea Pharmaceutica International Ltd, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
08/04/2026
Biotecnología
Anuncios breves
Política Internacional
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
Fuente
Basilea Pharmaceutica International Ltd, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
22/03/2026
Biotecnología
Anuncios breves
Basilea announces start of first‑in‑human study of novel antibiotic BAL2420
Fuente
Basilea Pharmaceutica International Ltd, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
24/02/2026
Biotecnología
Anuncios breves
Política Internacional
Basilea receives further USD 6 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
Fuente
Basilea Pharmaceutica International Ltd, Allschwil
Editor
GLOBENEWSWIRE
1.00
0
16/02/2026
Biotecnología
Gestión empresarial/Administración de Empresas
Política Internacional
Basilea reports strong 2025 full-year results, surpassing revenue and operating profit guidance
Fuente
Basilea Pharmaceutica International Ltd, Allschwil
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0